High Purity 99.0%min. Desmopressin Acetate DDAVP Lyophilized powder Peptide CAS NO.:16679-58-6 Research Chemical
Product Information:
INCI Name: Desmopressin Acetate DDAVP
Cas No: 16679-58-6
Molucular Formula: C46H64N14O12S2
Molecular Weight: 1069.22
Sequence: : Mpr-Tyr-Phe-Gln-Asn-Cys-Pro-DArg-Gly-NH2
Purity: >99%
Source: Synthetic
Grade: Cosmetic
Stability: Stable
Solubility: Slightly soluble in water
Formulation: Available for your reference, please contact us
MSDS and COA: Available for your reference, please contact us
Appearance: White Lyophilized powder
Storage:After reconstitution store at 2°C - 8°C
Description
Desmopressin acetate(DDAVP, Stimate) is synthetic 1-desamino-8-D-argininevasopressin. Its efficacy, ease of administration (intranasal),long duration of action, and lack of side effects make itthe drug of choice for the treatment of central diabetesinsipidus. It may also be administered intramuscularly orintravenously. It is preferred to vasopressin injectionand oral antidiuretics for use in children. It is indicatedin the management of temporary polydipsia and polyuriaassociated with trauma to, or surgery in, the pituitary region.
Application
Desmopressin, as its acetate salt, is a synthetic analogue of vasopressin in which the Nterminal Cys is devoid of its α-amino function (1-Deamino) and where Arg8 is present as its D-isomer (D-Arg8), thus the commercial acronym DDAVP. The presence of D-Arg and the absence of the N-terminal amine in the desmopressin structure have increased its half-life such that it is available for oral, parenteral, or nasal use. It is used by all three of these routes of administration to prevent or control polydipsia (excessive thirst), polyuria, and dehydration of patients with diabetes insipidus caused by a deficiency of vasopressin. It also has been approved for the treatment of nocturnal enuresis (bed-wetting), which is believed to be caused by an absence of the normal night time rise in vasopressin levels.
Desmopressin is known to cause an increase in both plasma factor VIII (antihemophilic factor) and plasminogen activator. It therefore is approved by the U.S. FDA for use, parenterally and nasally, in reducing spontaneous or trauma-induced bleeding episodes in patients with hemophilia A and type I Von Willebrand's disease, provided that their plasma factor VIII activity is greater than 5%. Stimate, the nasal spray used in treating patients with hemophilia A and type I Von Willebrand's disease, is 15-fold the concentration of DDAVP nasal spray; the latter is used in treating diabetes insipidus.
Clarify:
Our peptides is just for Reseach&Lab use,not used on Human body.
The potential efficacy and application involved in the product introduction are all from the published literature, which has not been evaluated by the State Food and Drug Administration, and are only for reference, not for actual basis.
){kind=link}
){kind=link}